OncoMatch/Clinical Trials/NCT07719361
A Study in Patients With Metastatic Castration-Resistant Prostate Cancer
Is NCT07719361 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1 trial studies FX-111 for metastatic castration resistant prostate cancer.
Treatment: FX-111 — The goal of this clinical trial is to find out if FX-111 is safe enough to permit further studies in adult male participants with metastatic castration-resistant prostate cancer (mCRPC). It will also study the drug's pharmacokinetics (how the body breaks down FX-111) and how well FX-111 treats mCRPC. The main questions it aims to answer are: What are the side effects of FX-111? Does FX-111 work to reduce or prevent progression of mCRPC? The study doctor will oversee participants' treatment with FX-111 and ask about any side effects. Participants will take FX-111 every day by mouth and will have regular physical and laboratory examinations to check health and tumor status.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Prostate Cancer
Disease stage
Required: Stage IV
Metastatic disease required
Metastatic Castration-Resistant Prostate Cancer
Demographics
Prior therapy
Must have received: androgen receptor pathway inhibitor (apalutamide, darolutamide, abiraterone, enzalutamide) — castration-sensitive or castration-resistant prostate cancer
Progressed on Androgen Deprivation Therapy (ADT) and at least one prior potent Androgen Receptor (AR) pathway inhibitor given in castration-sensitive prostate cancer setting or approved for castration-resistant prostate cancer (eg, apalutamide, darolutamide, abiraterone, enzalutamide)
Cannot have received: androgen receptor degrader or AR ligand-directed therapy
Prior treatment with AR degraders and molecules with an AR ligand such as AR Regulated Induced Proximity Targeting Chimera (RIPTAC)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- START Los Angeles · Los Angeles, California
- Massachusetts General Hospital · Boston, Massachusetts
- START Midwest · Grand Rapids, Michigan
- START New Jersey · East Brunswick, New Jersey
- START Carolinas · Myrtle Beach, South Carolina
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07719361 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior androgen receptor degrader or AR ligand-directed therapy disqualifies patients from enrollment.
What disease stage is eligible?
Stage IV is required (metastatic disease required).
Is this trial open to female patients?
No. This trial enrolls male patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages